A New Hope: Dual Human Epidermal Growth Factor Receptor 2 Blockade and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Amplified Colorectal Cancer - A Case Report and Literature Review.

ABSTRACT:

Introduction

Monoclonal antibodies targeting epidermal growth factor receptors (EGFRs) are currently the preferred targeted therapeutic agents for RAS wild-type, left-sided metastatic colorectal cancer (mCRC). Nonetheless, certain molecular alterations within mCRC confer resistance to anti-EGFR monoclonal antibody therapy, notably alterations involving human epidermal growth factor receptor 2 (HER2). Colorectal cancer (CRC) characterized by HER2 amplification or overexpression may have markedly different prognoses than HER2-negative CRC does. Recent clinical trials have demonstrated that dual HER2 blockade leads to significant improvements in clinical outcomes for these patients.

Case presentation

In this study, we present a case in which HER2-positive mCRC was successfully

SUBMITTER: Tang W 

PROVIDER: S-EPMC12685357 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature